Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 51,555

Document Document Title
WO/2017/095237A1
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to prot...  
WO/2017/094260A1
The present invention provides a method for manufacturing a mesenchymal cell line derived from vertebrate animal adipose tissue, as well as mesenchymal cell lines derived from vertebrate animal adipose tissue that are manufactured using ...  
WO/2017/095904A1
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin ...  
WO/2017/091757A1
Described herein are deuterated analogs of betrixaban, pharmaceutical compositions comprising the same, and methods of using the same.  
WO/2017/091449A1
Systems and methods for regulating fluid volume from an isolated cardiac circuit during cardiopulmonary bypass surgery are described. In one embodiment, a system in accordance with the present technology can include a pressure-regulated ...  
WO/2017/087391A1
Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic ...  
WO/2017/084644A1
The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)meth yl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4 ,5-triol5 a...  
WO/2017/083371A1
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of ...  
WO/2017/079921A1
A traditional Chinese medicine having a water disinhibiting function. The raw materials of the traditional Chinese medicine comprise: 32.4 g of bark of Chinese Redbud, 15 g of Abrus herb, 10 g of Aleurites moluccana, 5 g of Arabian jasmi...  
WO/2017/083440A1
Described herein are unit-dose formulations of 1, 1 '-[1,4-phenylenebis (methylene)]-bis- 1,4,8,1 l-tetraazacyclotetradecane ("AMD3100") and uses thereof as an anti-fugetactic agent.  
WO/2017/080043A1
An antithrombotic composition comprises an effective dose of 0.5 to 5 mg of ADP receptor antagonist and an effective dose of 30 to 70 mg of dabigatran etexilate, both components being in a free state or a pharmaceutically acceptable salt...  
WO/2017/083599A1
The present invention relates to biomarkers and diagnostic and prognostic methods for vascular diseases. In particular, proteins of platelet-derived exosomes have been identified as biomarkers that can be used to detect platelet activati...  
WO/2017/075845A1
Disclosed is use of aminothiazole MyD88-specific inhibitor TJM2010-5. In the present invention, a compound TJM2010-5 is used in prevention of myocardial ischemic reperfusion injury, limb replantation related ischemic reperfusion injury, ...  
WO/2017/078571A1
The invention relates to the field of the pharmaceutical industry and medicine, and more particularly to novel pegylated derivatives of erythropoiesis factors, and concerns the creation of novel molecules of low-sialylated darbepoetin an...  
WO/2017/077964A1
The present invention provides a method for preparing platelets, the method comprising a step for culturing megakaryocytic cells in a culture solution within a culture vessel, wherein, at said culturing step, the culture solution is stir...  
WO/2017/076968A1
The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterizedby reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic diso...  
WO/2017/079591A3
In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffe...  
WO/2017/079556A1
The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a t...  
WO/2017/076345A1
The present invention relates to a use of a compound of general formula (I) or its pharmaceutically acceptable salt in preparing a drug for preventing and/or treating cytopenia of a subject to receive, currently receiving, or having rece...  
WO/2017/073232A1
The present invention addresses the problem of providing a neural vascular barrier failure inhibitor, said inhibitor acting on vascular barrier failures caused not only by a hypoxic state but also by various other factors, and a therapeu...  
WO/2017/073536A1
The present invention addresses the problem of providing an aptamer for vWF, which is superior in a binding ability, a dissociation rate and/or stability to the conventional nucleic acid aptamers. The present invention can solve the prob...  
WO/2017/075150A1
A method of treatment for third spacing is provided. The method includes identifying an adverse factor, which includes conditions causing an increase in vascular permeability resulting in third spacing. The method also includes diagnosin...  
WO/2017/074798A3
Long-acting co-agonists of the glucagon and GLP-1 receptors are described.  
WO/2017/068089A9
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a l...  
WO/2017/068090A1
The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in ...  
WO/2017/068089A3
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a l...  
WO/2017/070167A1
The present invention provides Factor IX fusion proteins with higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein.  
WO/2017/067110A1
Use of NADPH in preparation of platelet aggregation inhibitors. according to the research, it is found that in-vitro administration of exogenous NADPH inhibits ADP-induced platelet aggregation of rats in a dose-dependent mode; in-vitro a...  
WO/2017/066863A1
The present invention provides compounds of Formula I: wherein Y, AA, W, R3, R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate for...  
WO/2017/065280A1
The present invention provides a method for producing purified platelets from a megakaryocyte culture, said method including a first centrifugation step in which the culture is centrifuged at a centrifugal force of 150×g to 550×g, and ...  
WO/2017/063328A1
A fullerene and/or metallofullerene micronano material and application thereof. The fullerene and/or metallofullerene micronano material has all the following properties: (1) the surface is hydrophilic, so that the micronano material is ...  
WO/2017/063103A1
The present invention relates to 2,5-diaminopyrimidine-based Bruton's tyrosine kinase inhibitors. The present invention also relates to 2,5-diaminopyrimidine-based affinity probes for Bruton's tyrosine kinase and uses of such probes for ...  
WO/2017/064213A1
The invention provides a derivative of platelet basic protein, such as connective tissue activating peptide III (CTAPIII), beta-thromboglobulin or neutrophil- activating peptide (NAP-2), for use in treatment or prophylaxis of a bleeding ...  
WO/2017/064615A1
The present invention relates to methods of using drugs, e.g. antibodies such as e.g. anti-C5 antibodies, disease that are capable of inhibiting the complement pathway for treating Transplant Associated Microangiopathy, in particular aft...  
WO/2017/063155A1
The present invention provides compounds of formula I. The present invention also provides a preparation method for the compounds and a medicine composition comprising the compounds. The medicine composition can be used for treating a bo...  
WO/2017/059623A1
The present invention relates to the field of pharmaceutical chemistry. In particular, the present invention relates to a class of alkynyl pyridine prolyl hydroxylase inhibitors (I). The experiment shows that such a compound has a good a...  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/055908A1
Provided are methods for clinical treatment of an ADAMTS 13 deficiency by administering an anti-C5 antibody, or antigen binding fragment thereof. Also, provided are methods for clinical treatment of congenital Thrombotic Thrombocytopenic...  
WO/2017/058436A1
A method for manufacturing a pharmaceutical composition for reducing the frequency of urination is disclosed. The pharmaceutical composition comprises (1) an analgesic agent and (2) an a-blocker, a 5α-reductase inhibitor or both.  
WO/2017/057541A1
The present invention provides a transdermal absorption preparation comprising a support and a drug-containing layer, wherein the drug-containing layer includes riociguat as the active ingredient, and a hydroxy acid or phosphoric acid.  
WO/2017/058074A1
The present invention relates to the use of gliadin in medicine, in combination with gammma aminobutyric acid, and/or an antigen such as a beta cell autoantigen.  
WO/2017/051208A1
The present disclosure relates, according to some embodiments, to acetogenin molecules that may have antiplatelet and/or antithronibic activities. In some embodiments, the present disclosure relates to an acetogenin molecule selected fro...  
WO/2017/048792A1
A pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms lipid carrying micelles or liposomes having a lipophilic c...  
WO/2017/047769A1
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...  
WO/2017/047776A1
Provided is a blood tryptophan concentration elevation inhibitor. The blood tryptophan concentration elevation inhibitor has, as an effective component thereof, lactic acid bacterium of the genus Lactobacillus, a processed product thereo...  
WO/2017/048157A1
The invention relates to medicine and can be used in the pharmaceutical industry, and relates to the combined use of an antifibrinolytic and a substance which has SERPING1 activity to treat a condition affecting a mammal's body, which is...  
WO/2017/046809A1
Compositions comprising a citrate salt and a calcium carbonate-containing material, articles-of-manufacturing and kits comprising same and uses thereof for inducing blood coagulation and/or for reducing or arresting hemorrhaging, particu...  
WO/2017/042731A1
The present invention provides a process for the preparation of amorphous form of selexipag (Ia). The present invention also provides a novel amorphous form of selexipag sodium (Ib) and selexipag potassium (Ic) and methods for preparing ...  
WO/2017/041266A1
Provided is a wine for invigorating Qi and promoting blood circulation, which consists of: 20 grams of milk vetch root, 10 grams of doubleteeth pubescent angelica root, 10 grams of Divaricate Saposhnikovia root, 10 grams of prepared liqu...  
WO/2017/043563A1
The present invention relates to a method for producing a compound represented by formula (1) or a salt thereof, comprising a step of reacting a compound represented by formula (2) or a salt thereof with a compound represented by formula...  

Matches 451 - 500 out of 51,555